Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.
Chemotherapy-induced Cardiotoxicity|Breast Cancer
DRUG: Rosuvastatin 20mg
change in left ventricular ejection fraction(LVEF) detected by electrocardiography transthoracic echocardiography, Patients will undergo transthoracic echocardiography 24 hours prior to the initiation of chemotherapy, after 3 months and after 6 months to detect change in LVEF, 6 months
change of serum level of High sensitivity troponin I (hs-TnI)., Blood samples will be collected at baseline, after 3 months and after 6 months to evaluate High sensitivity troponin I (hs-TnI)., 6 months|change of serum level of Myeloperoxidase (MPO)., Blood samples will be collected at baseline, after 3 months and after 6 months to evaluate Myeloperoxidase (MPO)., 6 months|change of serum level of Interleukin-6 (IL-6). > Liver function test (ALT)., Blood samples will be collected at baseline, after 3 months and after 6 months to evaluate Interleukin-6 (IL-6)., 6 months|change of serum level of Liver function test (ALT)., Blood samples will be collected at baseline, after 3 months and after 6 months to evaluate Liver function test (ALT)., 6 months
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.